CORTCorcept TherapeuticsFinished
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.4
3 insiders sold shares within a month
Since Aug 26, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 3
- Patients
- 137 (final count)
- Started
- Jul 27, 2020
- Main results expected
- Sep 19, 2024
- Fully finished
- Sep 19, 2024
- Results posted
- Aug 3, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change in Average 24-hour SBP
Measured over: Baseline and Week 22
Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.
Measured over: Baseline and up to Week 26
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.4, since 2026-08-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04308590 · record last updated 2025-09-04 · checked 2026-11-09 15:42 UTC